Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
131 hedge funds and large institutions have $958M invested in Mersana Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 40 reducing their positions, and 19 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 40
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less ownership
Funds ownership: 4.06% → 4.06% (-0%)
1% less funds holding
Funds holding: 132 → 131 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
16% less capital invested
Capital invested by funds: $1.14B → $958M (-$186M)
99% less call options, than puts
Call options by funds: $37K | Put options by funds: $3.75M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$15.8M |
| 2 |
O
OrbiMed
New York
|
+$13.7M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.9M |
| 4 |
BlackRock
New York
|
+$12.4M |
| 5 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.4M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$11.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.94M |
| 4 |
Goldman Sachs
New York
|
-$8.79M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.56M |
MRSN Hedge Fund Activity: Q2 2021 in Review
131 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q2 2021, worth a combined $958M — down 16% from $1.14B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MRSN and 18 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 50 added.
The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $15.8M. The largest seller was Point72 Asset Management, cutting an estimated $15.4M.
- 131 institutional investors held Mersana Therapeutics (MRSN) as of Q2 2021, down from 132 in Q1 2021.
- Funds reported $958M of Mersana Therapeutics stock for Q2 2021, down 16% quarter-over-quarter.
- 18 funds opened new Mersana Therapeutics positions in Q2 2021 and 19 closed out, a net change of -1 holder.
- The largest Mersana Therapeutics buyer in Q2 2021 was Assenagon Asset Management, an estimated $15.8M added.
- The largest Mersana Therapeutics seller in Q2 2021 was Point72 Asset Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2021.